Shionogi enrolls first sufferers within the Esprit examine for Pompe illness
Shionogi has enrolled the primary sufferers in its international Part II scientific trial, Esprit, evaluating investigational drug S-606001 in adults with late-onset Pompe illness (LOPD).
The randomized, multicenter, double-blind, placebo-controlled trial will embrace members from throughout the European Union, Nice Britain and the US.
Uncover B2B advertising and marketing that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra data
This 52-week examine will examine the pharmacodynamics, preliminary efficacy and security of S-606001 as oral substrate discount remedy (SRT), used along with normal enzyme substitute remedy (ERT) in adults with confirmed LOPD.
Pompe illness is a uncommon genetic metabolic illness that impacts each kids and adults. It’s brought on by a deficiency of acid alpha-glucosidase (GAA), which results in irregular accumulation of glycogen in tissues, particularly muscle mass.
S-606001 is an investigational SRT thought to scale back glycogen accumulation in muscle lysosomes by blocking glycogen synthase (GYS1). ERT will increase GAA enzyme ranges to advertise the breakdown of glycogen, whereas SRT goals to scale back glycogen manufacturing.
By focusing on totally different points of glycogen metabolism, SRT can be utilized alone or together with ERT.
Juan Carlos Gomez, chief medical officer of Shionogi, mentioned: “At the moment ERTs are the usual therapy for LOPD, however their efficacy could lower over time, resulting in continued decline in skeletal muscle perform.
“There’s a vital unmet want for brand spanking new therapy approaches that may be complementary to current remedies to additional gradual illness development.”
In 2024, Shionogi obtained unique worldwide rights to S-606001 from Maze Therapeutics. The drug was granted uncommon pediatric illness standing by the US Meals and Drug Administration (FDA) in 2025 and orphan drug standing in 2022. The protection and effectiveness of S-606001 haven’t been established.
In January 2025, Shionogi’s oral antiviral in opposition to respiratory syncytial virus (RSV) met its major endpoint in a section II trial. Some members achieved an 88.94% discount in viral load.
